Connect Biopharma Holdings Limited (CNTB) News
Filter CNTB News Items
CNTB News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CNTB News Highlights
- For CNTB, its 30 day story count is now at 5.
- Over the past 15 days, the trend for CNTB's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- AG, CRSP and NOV are the most mentioned tickers in articles about CNTB.
Latest CNTB News From Around the Web
Below are the latest news stories about CONNECT BIOPHARMA HOLDINGS LTD that investors may wish to consider to help them evaluate CNTB as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayPre-market stock movers are a hot topic on Wednesday as we check out all of the biggest movements happening this morning! |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayIt's time to start Tuesday trading with a breakdown of the biggest pre-market stock movers worth keeping an eye on this morning! |
Connect Biopharma and Simcere Announce Exclusive Licensing and Collaboration Agreement in Greater ChinaSimcere has been granted an exclusive right to develop, manufacture, and commercialize rademikibart for all indications in Greater ChinaConnect Biopharma retains rights to develop and commercialize rademikibart in all other markets and completed the pivotal atopic dermatitis (AD) trial in ChinaRademikibart is a human monoclonal antibody against IL-4Rα, a common subunit for IL-4R and IL-13 receptors being developed for the treatment of Th2 driven inflammatory diseases SAN DIEGO, CA and TAICANG, C |
Connect Biopharma Announces Positive Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic DermatitisClinical response (IGA 0/1 and EASI-75) achieved at Week 16 with rademikibart treatment was maintained through Week 52 with both every two weeks (Q2W) and every four weeks (Q4W) dosing regimens Approximately 90% of patients on Q4W dose maintained both IGA 0/1 and EASI-75 through Week 52 Over 36 weeks of treatment in Stage 2 of the study, the percentage of patients achieving IGA 0/1 and EASI-75 continued to increaseRademikibart continued to be well tolerated over 52 weeks of treatmentA conference |
Connect Biopharma to Announce Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis on November 21, 2023SAN DIEGO, CA and TAICANG, China, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced that it will announce topline results from the Stage 2 (maintenance period) of its China pivotal trial evaluating rademiki |
Connect Biopharma Holdings Limited's (NASDAQ:CNTB) largest shareholders are private equity firms with 41% ownership, insiders own 22%Key Insights Connect Biopharma Holdings' significant private equity firms ownership suggests that the key decisions are... |
Is Connect Biopharma Holdings (CNTB) Outperforming Other Medical Stocks This Year?Here is how Connect Biopharma Holdings Limited Sponsored ADR (CNTB) and CRISPR Therapeutics AG (CRSP) have performed compared to their sector so far this year. |
Has Connect Biopharma Holdings (CNTB) Outpaced Other Medical Stocks This Year?Here is how Connect Biopharma Holdings Limited Sponsored ADR (CNTB) and Haemonetics (HAE) have performed compared to their sector so far this year. |
Connect Biopharma Holdings Limited Sponsored ADR (CNTB) Upgraded to Buy: What Does It Mean for the Stock?Connect Biopharma Holdings Limited Sponsored ADR (CNTB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
Connect Biopharma Reports First Half 2023 Financial Results and Provides Business UpdateKey data readouts with Company’s lead drug candidate rademikibart expected in the fourth quarter of 2023 Topline results from Stage 2 of the China pivotal trial in atopic dermatitisTopline results from Global Phase 2 trial in asthma Cash balance of $131.6 million expected to support planned operations into at least 2026 SAN DIEGO and TAICANG, China, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage |